GlassScriptPhysician profile
Ronald G Ryder
NPI 1154309532
$90,669.61
in general payments reported to CMS, 2019-2025
35 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $18K · 2021: $6,859 · 2022: $9,378 · 2023: $783 · 2024: $726 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63,286.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $13,030.16 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $7,112.06 | 2021-2025 | |
| Esperion Therapeutics, INC. | $1,646.53 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $1,398.04 | 2021-2023 | Seglentis, Livalo |
| Amgen INC. | $625.55 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $519.38 | 2019-2025 | |
| Boston Scientific Corporation | $477.85 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.89 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $327.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.22 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $178.24 | 2019-2024 | Camzyos |
| Novo Nordisk INC | $175.98 | 2021-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $145.07 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $118.81 | 2022-2023 | Onpattro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $113.10 | 2022-2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $102.31 | 2019-2022 | |
| Scpharmaceuticals INC. | $101.80 | 2024 | |
| United Therapeutics Corporation | $98.16 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $95.64 | 2021-2025 | Opsumit, Uptravi |
| Altathera Pharmaceuticals LLC | $95.08 | 2020-2024 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals International, Plc | $69.30 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $66.78 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $61.42 | 2021 | |
| Philips North America LLC | $57.75 | 2023 | |
| Daiichi Sankyo INC. | $40.65 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.82 | 2019 | |
| Impulse Dynamics (USA) INC. | $24.58 | 2025 | Optimizer |
| Medicure Pharma INC. | $23.46 | 2021 | |
| Atricure, INC. | $23.08 | 2022 | |
| Edwards Lifesciences Corporation | $17.14 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.50 | 2022 | |
| Cmp Pharma, INC. | $15.68 | 2022 | |
| Amryt Pharma Holdings LTD | $14.55 | 2021 | |
| Astellas Pharma US INC | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.